Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 9/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20354320 | 0.81 | MTNR1A (0.50) | MTNR1AMTNR1BGABRA1GABRB2ELANE | |
| SCHEMBL27610316 | 0.81 | MTNR1A (0.62) | MTNR1AMTNR1BHTR2AHTR2CKCNH2 | |
| SCHEMBL15887325 | 0.81 | MTNR1A (0.60) | MTNR1AMTNR1BELANEHTR2AHTR2C | |
| SCHEMBL11785137 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BGABRA1GABRB2ELANE | |
| SCHEMBL1272629 | 0.81 | MTNR1A (0.50) | MTNR1AMTNR1BELANEHTR2AHTR2C | |
| SCHEMBL17361326 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BELANEHTR2AHTR2C | |
| SCHEMBL3819476 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BELANEHTR2AHTR2C | |
| SCHEMBL21067244 | 0.81 | MTNR1A (0.49) | MTNR1AMTNR1BGABRA1GABRB2ELANE | |
| SCHEMBL12053305 | 0.78 | MTNR1A (0.52) | MTNR1AMTNR1BHTR2AHTR2C | |
| SCHEMBL5541930 | 0.78 | MTNR1A (0.54) | MTNR1AMTNR1BELANEHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023098815-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 上海栖臻医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023020518-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023015240-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA UK LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| WO-2020113554-A1 | QUINOLINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | 东莞市东阳光农药研发有限公司 | 2020-06-11 | — | — | WO | disclosed |
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-06-25 | — | — | US | disclosed |
| US-8367695-B2 | Condensed tetrahydroquinoline derivative and use thereof for medical purposes | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | AERPIO THERAPEUTICS INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| US-8119693-B2 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-02-21 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | MTNR1A 3091/4885MTNR1B 3129/4885GABRA1 4596/4885 |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | MTNR1A 4097/4885MTNR1B 3636/4885GABRA1 2769/4885 |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | ALPI, SI, FABP2 | MTNR1A 1702/4885MTNR1B 2000/4885GABRA1 4334/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | MTNR1A 3091/4885MTNR1B 3129/4885GABRA1 4596/4885 |
| US-20100063055-A1 | CONDENSED TETRAHYDROQUINOLINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | NR3C2, MC2R, NR5A1 | MTNR1A 96/4885MTNR1B 92/4885GABRA1 632/4885 |
| US-20130023542-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | MTNR1A 4321/4885MTNR1B 3877/4885GABRA1 4556/4885 |
| US-10328078-B2 | Pteridine dione monocarboxylate transporter inhibitors | SLC16A1, SLC16A3, SLC16A7 | MTNR1A 667/4885MTNR1B 529/4885GABRA1 3305/4885 |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | OPRL1, OPRK1, OPRM1 | MTNR1A 78/4885MTNR1B 131/4885GABRA1 67/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | MTNR1A 3819/4885MTNR1B 3614/4885GABRA1 3975/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | MTNR1A 4321/4885MTNR1B 3877/4885GABRA1 4556/4885 |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, ALDH7A1 | MTNR1A 2631/4885MTNR1B 2433/4885GABRA1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.